Meeting NewsVideo

VIDEO: Durvalumab represents ‘major step forward’ in lung cancer

NEW YORK — Melissa Johnson, MD, associate director for lung cancer research at Sarah Cannon and a practicing partner in Tennessee Oncology, spoke at HemOnc Today New York about management of locally advanced non-small cell lung cancer.

She spoke extensively about durvalumab (Imfinzi, AstraZeneca), which she described as a new standard of care for patients with unresectable stage III NSCLC whose disease has not progressed after concurrent platinum-based chemotherapy and radiation therapy.

“This represents a major step forward in how we treat potentially curable patients with lung cancer,” Johnson told HemOnc Today. “It is one of the changes in our field that has longstanding implications.”

 

Disclosure: Johnson reports relationships with AbbVie, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Janssen, Merck, Novartis, Pfizer, Sanofi and several other pharmaceutical companies.

NEW YORK — Melissa Johnson, MD, associate director for lung cancer research at Sarah Cannon and a practicing partner in Tennessee Oncology, spoke at HemOnc Today New York about management of locally advanced non-small cell lung cancer.

She spoke extensively about durvalumab (Imfinzi, AstraZeneca), which she described as a new standard of care for patients with unresectable stage III NSCLC whose disease has not progressed after concurrent platinum-based chemotherapy and radiation therapy.

“This represents a major step forward in how we treat potentially curable patients with lung cancer,” Johnson told HemOnc Today. “It is one of the changes in our field that has longstanding implications.”

 

Disclosure: Johnson reports relationships with AbbVie, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Janssen, Merck, Novartis, Pfizer, Sanofi and several other pharmaceutical companies.

    See more from HemOnc Today New York